First Time Loading...

TCR2 Therapeutics Inc
NASDAQ:TCRR

Watchlist Manager
TCR2 Therapeutics Inc Logo
TCR2 Therapeutics Inc
NASDAQ:TCRR
Watchlist
Price: 1.48 USD Market Closed
Updated: May 20, 2024

TCR2 Therapeutics Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

TCR2 Therapeutics Inc
Research & Development Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
TCR2 Therapeutics Inc
NASDAQ:TCRR
Research & Development
-$98.4m
CAGR 3-Years
-38%
CAGR 5-Years
-59%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Research & Development
-$7.3B
CAGR 3-Years
-2%
CAGR 5-Years
-7%
CAGR 10-Years
-9%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$6B
CAGR 3-Years
18%
CAGR 5-Years
-3%
CAGR 10-Years
-10%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$5B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.5B
CAGR 3-Years
-24%
CAGR 5-Years
-19%
CAGR 10-Years
-14%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$4.6B
CAGR 3-Years
-17%
CAGR 5-Years
-16%
CAGR 10-Years
-17%

See Also

What is TCR2 Therapeutics Inc's Research & Development?
Research & Development
-98.4m USD

Based on the financial report for Dec 31, 2022, TCR2 Therapeutics Inc's Research & Development amounts to -98.4m USD.

What is TCR2 Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-59%

Over the last year, the Research & Development growth was -34%. The average annual Research & Development growth rates for TCR2 Therapeutics Inc have been -38% over the past three years , -59% over the past five years .